Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel

Malvezzi, 2013, European cancer mortality predictions for the year 2013, Ann Oncol, 24, 792, 10.1093/annonc/mdt010 Tannock, 2004, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, N Engl J Med, 351, 1502, 10.1056/NEJMoa040720 Italiano, 2009, Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer, Eur Urol, 55, 1368, 10.1016/j.eururo.2008.07.078 Lissbrant, 2013, Population-based study on use of chemotherapy in men with castration resistant prostate cancer, Acta Oncol, 52, 1593, 10.3109/0284186X.2013.770164 de Bono, 2011, Abiraterone and increased survival in metastatic prostate cancer, N Engl J Med, 364, 1995, 10.1056/NEJMoa1014618 Fizazi, 2012, Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study, Lancet Oncol, 13, 983, 10.1016/S1470-2045(12)70379-0 Ryan, 2013, Abiraterone in metastatic prostate cancer without previous chemotherapy, N Engl J Med, 368, 138, 10.1056/NEJMoa1209096 Scher, 2012, Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, 367, 1187, 10.1056/NEJMoa1207506 Kantoff, 2010, Sipuleucel-T immunotherapy for castration-resistant prostate cancer, N Engl J Med, 363, 411, 10.1056/NEJMoa1001294 de Bono, 2010, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, Lancet, 376, 1147, 10.1016/S0140-6736(10)61389-X Fizazi, 2011, Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study, Lancet, 377, 813, 10.1016/S0140-6736(10)62344-6 Smith, 2012, Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial, Lancet, 379, 39, 10.1016/S0140-6736(11)61226-9 Parker, 2013, Alpha emitter radium-223 and survival in metastatic prostate cancer, N Engl J Med, 369, 213, 10.1056/NEJMoa1213755 Goldhirsch, 2013, Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013, Ann Oncol, 24, 2206, 10.1093/annonc/mdt303 Armstrong, 2012, Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer, Eur Urol, 61, 549, 10.1016/j.eururo.2011.11.009 de Bono, 2008, Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer, Clin Cancer Res, 14, 6302, 10.1158/1078-0432.CCR-08-0872 Scher, 2011, J Clin Oncol, 29 Egan, 2011, Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells, PLoS One, 6, e26125, 10.1371/journal.pone.0026125 Sartor, 2013, Unmet needs in the prediction and detection of metastases in prostate cancer, Oncologist, 18, 549, 10.1634/theoncologist.2013-0027 Lecouvet, 2007, Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies, J Clin Oncol, 25, 3281, 10.1200/JCO.2006.09.2940 Tombal, 2005, Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases, Prostate, 65, 178, 10.1002/pros.20280 Loriot, 2012, Personalizing treatment in patients with castrate-resistant prostate cancer: a study of predictive factors for secondary endocrine therapies activity, J Clin Oncol, 30 Saad, 2004, Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer, J Natl Cancer Inst, 96, 879, 10.1093/jnci/djh141 Loriot, 2013, Towards random sequencing or precision medicine in castration-resistant prostate cancer?, Eur Urol Noonan, 2013, Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide, Ann Oncol, 24, 1802, 10.1093/annonc/mdt138 Loriot, 2013, Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100), Ann Oncol, 24, 1807, 10.1093/annonc/mdt136 Schrader, 2013, Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone, Eur Urol Bianchini, 2013, Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone, Eur J Cancer, 50, 78, 10.1016/j.ejca.2013.08.020 Press release. Dendreon announces marketing authorization for PROVENGE® in the European Union. Available at: <http://files.shareholder.com/downloads/DNDN/2679987622x0x691078/965100e2-bcfd-4fb0-a8cb-1189bfa53b43/DNDN_News_2013_9_17_General.pdf> [accessed October 2, 2013]. Merseburger, 2013, Perspectives on treatment of metastatic castration-resistant prostate cancer, Oncologist, 18, 558, 10.1634/theoncologist.2012-0478 Van Soest, 2013, Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer, Eur J Cancer, 49, 3821, 10.1016/j.ejca.2013.09.026 Fitzpatrick, 2013, Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer, Eur Urol Mezynski, 2012, Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?, Ann Oncol, 23, 2943, 10.1093/annonc/mds119 Albiges, 2012, Response to cabazitaxel in the postchemotherapy setting in CRPC patients previously treated with docetaxel and abiraterone acetate, Ann Oncol, 23 Mukherji, 2012, Response to abiraterone acetate in the postchemotherapy setting in patients with castration-resistant prostate cancer whose disease progresses early on docetaxel, J Clin Oncol, 30 Oudard, 2011, Management of metastatic castration-resistant prostate cancer (mCRPC) after an initial good response to first-line docetaxel (D): a retrospective study on 270 patients (pts), Eur J Cancer, 47 Pfister, 2012, Comparison of second-line treatments in patients with castration-resistant prostate cancer with PSA relapse after or during docetaxel chemotherapy, J Clin Oncol, 30 Heidenreich A, Bastian PJ, Bellmunt J, et al. European Association of Urology: guidelines on prostate cancer 2013. Available at: <http://www.uroweb.org/gls/pdf/09_Prostate_Cancer_LR.pdf> [accessed: October 2, 2013]. Horwich, 2013, Prostate cancer: ESMO Consensus Conference Guidelines 2012, Ann Oncol, 24, 1141, 10.1093/annonc/mds624 Sternberg, 2013, Treatment patterns and characteristics of European patients with castration-resistant prostate cancer, BMC Urol, 13, 58, 10.1186/1471-2490-13-58 Thuret, 2008, The postchemotherapy PSA surge syndrome, Ann Oncol, 19, 1308, 10.1093/annonc/mdn062 Angelergues, 2013, Retrospective registry evaluating the PSA flare phenomenon with cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC), J Clin Oncol, 31